Animal testing requirements for monoclonal antibodies and other medications will be “reduced, refined or potentially replaced” in favor of other approaches, including artificial intelligence, according to a recent announcement from the FDA.
“For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally,” FDA Commissioner Martin A. Makary, MD, MPH, said in a press release. “This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments